27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
On Tuesday, Supernus Pharmaceuticals (NASDAQ:SUPN) will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Supernus Pharmaceuticals EPS will likely be near 27 cents per share while revenue will be around $87.28 million, according to analysts.
In the same quarter last year, Supernus Pharmaceuticals reported EPS of 26 cents per share on revenue of $62.37 million. The Wall Street estimate would represent a 3.85 percent increase in the company's earnings. Revenue would be up 39.93 percent from the year-ago period.
Supernus Pharmaceuticals' reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | 0.27 | 0.24 | 0.24 | 0.26 |
| EPS Actual | 0.29 | 0.32 | 0.19 | 0.26 |
Stock Performance
Over the last 52-week period, shares are up 55.42 percent. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Supernus Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.